Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study):A randomised, open label, superiority trial

Abhishek, Abhishek, Peckham, Nicholas, Pade, Corinna, Gibbons, Joseph M., Cureton, Lucy, Francis, Anne, Barber, Vicki, Williams, Jennifer A. E., Appelbe, Duncan, Eldridge, Lucy, Julier, Patrick, Altmann, Daniel M., Bluett, James, Brooks, Tim, Coates, Laura C., Rombach, Ines, Semper, Amanda, Otter, Ashley, Valdes, Ana M., Nguyen-Van-Tam, Jonathan S., Williams, Hywel C., Boyton, Rosemary J., McKnight, Áine and Cook, Jonathan A. and VROOM study investigators (2024) Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study):A randomised, open label, superiority trial. The Lancet Rheumatology, 6 (2). e92-e104. ISSN 2665-9913

[thumbnail of 1-s2.0-S2665991323002989-main]
Preview
PDF (1-s2.0-S2665991323002989-main) - Published Version
Available under License Creative Commons Attribution.

Download (735kB) | Preview

Abstract

Background: Methotrexate is the first-line treatment for immune-mediated inflammatory diseases and reduces vaccine-induced immunity. We evaluated if a 2-week interruption of methotrexate treatment immediately after COVID-19 booster vaccination improved antibody response against the S1 receptor binding domain (S1-RBD) of the SARS-CoV-2 spike protein and live SARS-CoV-2 neutralisation compared with uninterrupted treatment in patients with immune-mediated inflammatory diseases. Method: We did a multicentre, open-label, parallel-group, randomised, superiority trial in secondary-care rheumatology and dermatology clinics in 26 hospitals in the UK. Adults (aged ≥18 years) with immune-mediated inflammatory diseases taking methotrexate (≤25 mg per week) for at least 3 months, who had received two primary vaccine doses from the UK COVID-19 vaccination programme were eligible. Participants were randomly assigned (1:1) using a centralised validated computer program, to temporarily suspend methotrexate treatment for 2 weeks immediately after COVID-19 booster vaccination or continue treatment as usual. The primary outcome was S1-RBD antibody titres 4 weeks after COVID-19 booster vaccination and was assessed masked to group assignment. All randomly assigned patients were included in primary and safety analyses. This trial is registered with ISRCTN, ISRCTN11442263; following a pre-planned interim analysis, recruitment was stopped early. Finding: Between Sept 30, 2021, and March 7, 2022, we screened 685 individuals, of whom 383 were randomly assigned: to either suspend methotrexate (n=191; mean age 58·8 years [SD 12·5], 118 [62%] women and 73 [38%] men) or to continue methotrexate (n=192; mean age 59·3 years [11·9], 117 [61%] women and 75 [39%] men). At 4 weeks, the geometric mean S1-RBD antibody titre was 25 413 U/mL (95% CI 22 227–29 056) in the suspend methotrexate group and 12 326 U/mL (10 538–14 418) in the continue methotrexate group with a geometric mean ratio (GMR) of 2·08 (95% CI 1·59–2·70; p<0·0001). No intervention-related serious adverse events occurred. Interpretation: 2-week interruption of methotrexate treatment in people with immune-mediated inflammatory diseases enhanced antibody responses after COVID-19 booster vaccination that were sustained at 12 weeks and 26 weeks. There was a temporary increase in inflammatory disease flares, mostly self-managed. The choice to suspend methotrexate should be individualised based on disease status and vulnerability to severe outcomes from COVID-19. Funding: National Institute for Health and Care Research.

Item Type: Article
Additional Information: Funding Information: The study was funded by the NIHR–EME programme. Grant number: NIHR134607. Support was also received from the NIHR Oxford Biomedical Research Centre. The views expressed in this manuscript are those of its authors and not necessarily those of the National Health Service, NIHR, Department of Health and Social Care, or the Joint Committee on Vaccination and Immunisation. The study is sponsored by The University of Nottingham, Nottingham, UK and is managed by the Oxford Clinical Trials Research Unit (OCTRU). The co-authors would like to acknowledge the contribution of patient and public involvement volunteers in Oxford and Nottingham for their help in designing this study and members of OCTRU who enabled the rapid set-up of this study and have provided ongoing support. Funding Information: The study was funded by the NIHR–EME programme. Grant number: NIHR134607. Support was also received from the NIHR Oxford Biomedical Research Centre. The views expressed in this manuscript are those of its authors and not necessarily those of the National Health Service, NIHR, Department of Health and Social Care, or the Joint Committee on Vaccination and Immunisation. The study is sponsored by The University of Nottingham, Nottingham, UK and is managed by the Oxford Clinical Trials Research Unit (OCTRU). The co-authors would like to acknowledge the contribution of patient and public involvement volunteers in Oxford and Nottingham for their help in designing this study and members of OCTRU who enabled the rapid set-up of this study and have provided ongoing support. Publisher Copyright: © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
Uncontrolled Keywords: rheumatology,immunology and allergy,immunology,sdg 3 - good health and well-being ,/dk/atira/pure/subjectarea/asjc/2700/2745
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Related URLs:
Depositing User: LivePure Connector
Date Deposited: 04 Mar 2024 18:39
Last Modified: 04 Mar 2024 18:39
URI: https://ueaeprints.uea.ac.uk/id/eprint/94560
DOI: 10.1016/S2665-9913(23)00298-9

Actions (login required)

View Item View Item